{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Unknown/Unavailable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"}],"units":"Participants"}],"description":"The frequency of best overall tumor response summarized by response category. The best (unconfirmed) response recorded from the start of chemotherapy treatment until disease progression/recurrence, start of any further anti-tumor therapy, or time of surgery whichever comes first.","groups":[{"description":"pemetrexed: 500 mg/m2, intravenous, every 21 days x 4 cycles cisplatin: 75 mg/m2, intravenous, every 21 days x 4 cycles chemotherapy, surgery then chest radiation x 54 gray (Gy)","id":"OG000","title":"Pemetrexed"}],"paramType":"NUMBER","populationDescription":"Intention to Treat analysis. All enrolled participants who were eligible for the treatment, whether or not they received the study drug.","reportingStatus":"POSTED","timeFrame":"baseline to measured progressive disease","title":"Overall Tumor Response","type":"SECONDARY","unitOfMeasure":"participants"}